2. Search Result
Search Result
Results for "

IFN-γ/STAT1/SLC7A11 axis

" in MedChemExpress (MCE) Product Catalog:

637

Inhibitors & Agonists

2

Screening Libraries

4

Fluorescent Dyes

8

Biochemical Assay Reagents

63

Peptides

2

MCE Kits

71

Inhibitory Antibodies

111

Natural
Products

51

Recombinant Proteins

28

Isotope-Labeled Compounds

22

Antibodies

5

Click Chemistry

16

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15763
    Erastin
    Maximum Cited Publications
    805 Publications Verification

    		 VDAC Ferroptosis Disulfidptosis Cancer
    Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation [1] .
    Erastin
  • HY-B0069
    Fludarabine
    100+ Cited Publications

    F-ara-A; NSC 118218

    		 Nucleoside Antimetabolite/Analog DNA/RNA Synthesis STAT Apoptosis Cancer
    Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes [1] .
    Fludarabine
  • HY-112288
    C188-9
    30+ Cited Publications

    TTI-101

    		 STAT Apoptosis DNA Methyltransferase Metabolic Disease Inflammation/Immunology Cancer
    C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia [1] .
    C188-9
  • HY-107429
    Abrocitinib
    10+ Cited Publications

    PF-04965842

    		 JAK Inflammation/Immunology
    Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease [1].
    Abrocitinib
  • HY-P99191
    Emapalumab

    NI-0501

    		 IFNAR Inflammation/Immunology
    Emapalumab (NI-0501) is a human monoclonal IgG1 antibody that noncompetitively inhibits IFN-γ. Emapalumab binds with high affinity (Kd= 1.4 pM) to both free IFN-γ as well as IFN-γ bound to its receptor. Emapalumab can be used in research of hemophagocytic lymphohistiocytosis (HLH) [1].
    Emapalumab
  • HY-P4717
    IFN-γ Antagonist 1

    		IFNAR Inflammation/Immunology
    IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) is an interferon-γ (IFN-γ) antagonist. IFN-γ Antagonist 1 inhibits IFN-γ-induced HLR/DR antigen expression in cells. IFN-γ Antagonist 1 can be used in researches of diseases with abnormal immune regulation [1].
    IFN-γ Antagonist 1
  • HY-W013523
    2-NP
    10+ Cited Publications

    		 STAT JAK HSV Infection Cancer
    2-NP is a selective enhancer of STAT1 transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells [1].
    2-NP
  • HY-170621
    STAT1/3-IN-1

    		STAT NO Synthase COX Interleukin Related TNF Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    STAT1/3-IN-1 is a potent STAT1/3 inhibitor with potent anti-inflammatory effect. STAT1/3-IN-1 inhibits phosphorylation and nuclear translocation of STAT1/3 to modulate microglial inflammation, reduces LPS (HY-D1056)-induced pro-inflammatory cytokines (NO, IL-1β, IL-6, and TNF-α) and inflammatory mediators (iNOS, COX-2). STAT1/3-IN-1 exhibits low toxicity in mice. STAT1/3-IN-1 can be used for the research of neuroinflammation [1].
    STAT1/3-IN-1
  • HY-W451275
    HG106
    2 Publications Verification

    		 Apoptosis Cancer
    HG106 is an effective SLC7A11 inhibitor. HG106 mediates apoptosis by increasing oxidative stress and endoplasmic reticulum stress, and it has antitumor activity [1].
    HG106
  • HY-P990798
    Anti-Mouse IFN gamma Antibody (XMG1.2)

    		IFNAR Inflammation/Immunology Cancer
    Anti-Mouse IFN gamma Antibody (XMG1.2) is a kind of rat-derived IgG1 antibody inhibitor, targeting to IFN-γ. Anti-Mouse IFN gamma Antibody (XMG1.2) can neutralize IFN-γ. Anti-Mouse IFN gamma Antibody (XMG1.2) can be used for the researches of cancer, inflammation and immunology, such as multiple myeloma and chronic inflammation [1] .
    Anti-Mouse IFN gamma Antibody (XMG1.2)
  • HY-119024
    BCI-137

    		SHP1 STAT Cancer
    BCI-137 is a Argonaute 2 (AGO2) inhibitor. By inhibiting AGO2 function, reducing PTPN6/SHP-1 protein levels and enhancing STAT1 phosphorylation, BCI-137 restores the sensitivity of tumor cells to IFN-γ. BCI-137 effectively enhances the recruitment, activation and cytotoxicity of CD8 + T cells. BCI-137 exerts a synergistic effect with anti-PD-1 antibodies and significantly reduces tumor volume in preclinical mouse models. BCI-137 exhibits favorable safety profiles and does not cause significant weight loss or death in mice. BCI-137 can be used in research related to bladder cancer, colorectal cancer, melanoma and other related fields [1].
    BCI-137
  • HY-175032
    ATF3-IN-1

    		Ferroptosis Epigenetic Reader Domain Reactive Oxygen Species (ROS) Glutathione Peroxidase Cardiovascular Disease Neurological Disease
    ATF3-IN-1 is a ferroptosis and ATF3 inhibitor. ATF3-IN-1 inhibits oxidative stress and ferroptosis through the ATF3/SLC7A11/GPX4 pathway, exerting anti-ischemic stroke effects. ATF3-IN-1 can attenuate ischemia/reperfusion (I/R) injury and improve neuronal survival. ATF3-IN-1 has neuroprotective effects and can be used to study ischemic stroke [1].
    ATF3-IN-1
  • HY-136339
    Cbl-b-IN-1
    1 Publications Verification

    		 E1/E2/E3 Enzyme Interleukin Related Inflammation/Immunology Cancer
    Cbl-b-IN-1 (Example 519) is an inhibitor of Cbl-b, with an IC50 of less than 100 nM. Cbl-b-IN-1 can promote the secretion of cytokines such as IL-2, IFN-γ, and TNF-α, facilitate T cell activation, and enhance the TCR signaling pathway. Cbl-b-IN-1 can be used in research on immunomodulation [1] .
    Cbl-b-IN-1
  • HY-W018161
    Hexadecanedioic acid
    1 Publications Verification

    Thapsic acid

    		 IRE1 Ferroptosis Keap1-Nrf2 Glutathione Peroxidase Metabolic Disease
    Hexadecanedioic acid (Thapsic acid) is an orally active metabolite produced by B. uniformis. Hexadecanedioic acid inhibits IRE1α-XBP1s-mediated flipogenesis and ferroptosis. Hexadecanedioic acid downregulates XBP1 and Hrd1 expression, activates the Nrf2/SLC7A11/GPX4 pathway. Hexadecanedioic acid can be used for the research of metabolic-associated fatty liver disease [1].
    Hexadecanedioic acid
  • HY-114495
    Caerulomycin A
    3 Publications Verification

    Cerulomycin; Caerulomycin

    		 Fungal Antibiotic Infection Inflammation/Immunology
    Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma [1] .
    Caerulomycin A
  • HY-149979
    SLC7A11-IN-1

    		Apoptosis Cancer
    SLC7A11-IN-1 is a potent solute carrier family 7 member 11 (SLC7A11, xCT) inhibitor. SLC7A11-IN-1 shows antiproliferative activity. SLC7A11-IN-1 inhibits cell invasion and metastasis. SLC7A11-IN-1 induces Apoptosis and cell cycle arrest at S-phase. SLC7A11-IN-1 shows anti-tumor activity [1].
    SLC7A11-IN-1
  • HY-P4717A
    IFN-γ Antagonist 1 acetate

    		IFNAR Inflammation/Immunology
    IFN-γ Antagonist 1 (AYCRDGKIGPPKLDIRKEEKQI) acetate is an interferon-γ (IFN-γ) antagonist. IFN-γ Antagonist 1 acetate inhibits IFN-γ-induced HLR/DR antigen expression in cells. IFN-γ Antagonist 1 acetate can be used in researches of diseases with abnormal immune regulation [1].
    IFN-γ Antagonist 1 acetate
  • HY-115594
    Erasin

    		STAT Apoptosis Cancer
    Erasin is a potent Erlotinib (HY-50896)-resistance antagonizing STAT3 inhibitor with IC50s of 9.7 and 24 μM against STAT3 and STAT1, respectively. Erasin induces cancer cells apoptosis [1].
    Erasin
  • HY-119347
    Cirsilineol
    3 Publications Verification

    		 IFNAR STAT Inflammation/Immunology Cancer
    Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal CD4 + T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties. Cirsilineol significantly ameliorates trinitro-benzene sulfonic acid (TNBS)-induced T-cell-mediated experimental colitis in mice [1].
    Cirsilineol
  • HY-N10549
    Gigantol
    1 Publications Verification

    		 Ferroptosis c-Myc Glutathione Peroxidase JNK Reactive Oxygen Species (ROS) GSK-3 Infection Metabolic Disease Cancer
    Gigantol is an orally active bibenzyl compound. Gigantol targets MYC to promote its ubiquitin-proteasomal degradation and inhibit the growth of lung cancer cells. Gigantol exerts anti-lung cancer activity by inducing ferroptosis (Ferroptosis) via the SLC7A11-GPX4 axis. Gigantol restores the sensitivity of mcr-harboring multidrug-resistant bacteria to colistin. Gigantol ameliorates carbon tetrachloride-induced liver injury by inhibiting the activation of the JNK/cPLA2/12-LOX inflammatory pathway. Gigantol promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells. Gigantol can be used in studies related to diseases such as lung cancer, multidrug-resistant Gram-negative bacterial infections, and acute liver injury [1] .
    Gigantol
  • HY-RS13325
    SLC7A11 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SLC7A11 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC7A11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SLC7A11 Human Pre-designed siRNA Set A
    SLC7A11 Human Pre-designed siRNA Set A
  • HY-W008510
    2-Chloro-5-(trifluoromethyl)pyrimidine

    		Drug Intermediate STAT Others
    2-Chloro-5-(trifluoromethyl)pyrimidine is a chemical intermediate. It can be used in the synthesis of inducers of intracellular STAT1 phosphorylation [1].
    2-Chloro-5-(trifluoromethyl)pyrimidine
  • HY-B0653A
    Levobupivacaine hydrochloride
    2 Publications Verification

    (S)-(-)-Bupivacaine monohydrochloride

    		 Sodium Channel Ferroptosis Cardiovascular Disease Neurological Disease Cancer
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer [1] .
    Levobupivacaine hydrochloride
  • HY-W402682
    SXC2023

    		Amino acid Transporter Neurological Disease Cancer
    SXC2023 is a glutamatergic reagent and cystine-glutamate antiporter (System xc −) activator. SXC2023 can affect SLC7A11. SXC2023 is applicable to the research of colorectal cancer and trichotillomania [1] .
    SXC2023
  • HY-P99136
    Anti-Mouse IFN gamma Antibody (H22)
    1 Publications Verification

    		 IFNAR Infection Inflammation/Immunology
    Anti-Mouse IFN gamma Antibody (H22) is an anti-mouse IFN gamma IgG antibody inhibitor derived from host Armenian Hamster. Anti-Mouse IFN gamma Antibody (H22) abrogates specific binding of I25II-rIFN-γ to macrophages. Anti-Mouse IFN gamma Antibody (H22) inhibits macrophage-activating factor (MAF) (ID50 = 56 ng). Anti-Mouse IFN gamma Antibody (H22) inhibits IFN-gamma dependent antiviral activity (ID50 = 2 ng). Anti-Mouse IFN gamma Antibody (H22) neutralizes IFNγ in mice. Anti-Mouse IFN gamma Antibody (H22) can be used for the researches of inflammation and infection, such as arthritis [1] .
    Anti-Mouse IFN gamma Antibody (H22)
  • HY-158142
    PROTAC TYK2 degrader-1

    		PROTACs JAK STAT Inflammation/Immunology Cancer
    PROTAC TYK2 degrader-1 is a TYK2 PROTAC degrader with a Dmax ≥ 60%. PROTAC TYK2 degrader-1 reduces the phosphorylation levels of IFNα-induced STAT1 (Tyr701) and STAT3 (Tyr705) in immune cells. PROTAC TYK2 degrader-1 can be used in research on cancer, inflammatory diseases, etc. [1]
    PROTAC TYK2 degrader-1
  • HY-169056
    SLC7A11-IN-2

    		Reactive Oxygen Species (ROS) Cancer
    SLC7A11-IN-2 (Compound 1) is an SLC7A11/xCT inhibitor. SLC7A11-IN-2 induces cell death in HeLa cells by lowering intracellular glutathione levels and increasing oxidative stress, thereby disrupting the oxidative balance within the cells, with an IC50 value of 10.23 μM. Molecular dynamics simulation analysis indicates that SLC7A11-IN-2 has a stronger binding affinity to SLC7A11 compared to Erastin (HY-15763). SLC7A11-IN-2 can be utilized in research within the field of cervical cancer [1].
    SLC7A11-IN-2
  • HY-116940
    Sm4
    1 Publications Verification

    		 Oct3/4 Notch STAT Cancer
    Sm4 is a selective and orally active SOX18 inhibitor. Sm4 inhibits SOX18-DNA binding (IC50 = 97.5 μM); Sm4 disrupts the SOX18-RBPJ protein-protein interaction (IC50 = 42.3 μM). Sm4 blocks SOX18 DNA binding, disrupts multiple SOX18 protein-protein interactions with RBPJ, DDX1, DDX17, ILF3, SOX7 and STAT1, modulates SOX18 chromatin binding dynamics. Sm4 exerts anti‑angiogenic and anti‑lymphangiogenic effects, reduces tumor vascular density, triggers vascular defects in zebrafish, prolongs survival in mouse metastatic cancer models. Sm4 can be used for the research of breast cancer [1] .
    Sm4
  • HY-173679
    RBN012811

    		PROTACs PARP Interleukin Related STAT Integrin HSV VSV Infection Cancer
    RBN012811 is a highly selective PROTAC-based PARP14 degrader. RBN012811 forms a ternary complex with cereblon by binding to the NAD + site of PARP14, and mediates the specific degradation of PARP14 via the ubiquitin-proteasome pathway (IC50=10 nM). RBN012811 effectively depletes endogenous PARP14 in various cell lines and primary human macrophages, thereby downregulating IL-10 production and IFN-β mRNA levels, increasing phosphorylated STAT1 levels to enhance inflammatory signaling, and inhibiting interferon-induced ADPr condensate formation. RBN012811 also modulates viral replication, exhibiting increased HSV1 replication while reducing VSV replication. RBN012811 has important application value in research related to cancer and viral infections [1] .
    RBN012811
  • HY-P99666
    Interferon alfa-2b

    		IFNAR Infection Cancer
    Interferon alfa-2b is a type I interferon that activates novel genes and exerts potent antiviral and antiproliferative activity on target cells. Signaling by Interferon alfa-2b requires receptor-dependent activation of Stat1 and Stat2 to form a heterodimeric STAT that binds to the DNA-binding protein IRF-9 (p48) and forms ISGF-3 (IFN-stimulated gene factor 3). The driver genes are then further activated by ISGF-3 to achieve antiviral function [1].
    Interferon alfa-2b
  • HY-RS13886
    STAT1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    STAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STAT1 Human Pre-designed siRNA Set A
    STAT1 Human Pre-designed siRNA Set A
  • HY-122891
    SB02024
    1 Publications Verification

    		 PI3K CXCR STAT Cancer
    SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity [1] .
    SB02024
  • HY-125938
    Cycloartenyl ferulate
    1 Publications Verification

    Cycloartenol ferulate; Cycloartenol ferulic acid ester

    		 Drug Derivative Apoptosis Reactive Oxygen Species (ROS) JAK STAT Inflammation/Immunology Cancer
    Cycloartenyl ferulate (Cycloartenol ferulate; Cycloartenol ferulic acid ester) is a derivative of γ-oryzanol (HY-B2194) with multiple biological activities including antioxidant, anti-inflammatory, and anti-tumor properties. Cycloartenyl ferulate selectively binds to IFNγR1 (binding affinity Kd = 0.5 μM) to activate the canonical JAK1/2-STAT1 signaling pathway. Cycloartenyl ferulate inhibits paraquat (PQ)-triggered apoptosis and ROS in HK2 cells. Cycloartenyl ferulate enhances the activation and cytolytic activity of natural killer (NK) cells by upregulating the expression of NK cell activation receptors (NKG2D, NKp30, NKp44) and the release of cytotoxic molecules and cytokine IFNγ. Cycloartenyl ferulate exerts anti-cancer effects in tumor mice models. Cycloartenyl ferulate can be used for the study of cancer and allergic inflammation intervention [1] .
    Cycloartenyl ferulate
  • HY-161060
    Zharp1-211

    		RIP kinase STAT Inflammation/Immunology Cancer
    Zharp1-211 is a RIPK1 kinase inhibitor with an EC50 of 53 nM and a Kd of 8.7 nM. Zharp1-211 reduces IFN-γ-induced STAT1 activation. Zharp1-211 can be used in the research of graft-versus-host disease and colon cancer [1].
    Zharp1-211
  • HY-149007
    STAT3-IN-11
    1 Publications Verification

    		 STAT Apoptosis Cancer
    STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers [1].
    STAT3-IN-11
  • HY-RS16517
    Stat1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Stat1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Stat1 Mouse Pre-designed siRNA Set A
    Stat1 Mouse Pre-designed siRNA Set A
  • HY-P990839
    Anti-IFNγ Antibody (B133.5)

    		IFNAR Inflammation/Immunology
    Anti-IFNγ Antibody (B133.5) is a kind of mouse IgG1 chimeric antibody inhibitor, targeting to human IFNγ. Anti-IFNγ Antibody (B133.5) can neutralize human IFNγ (interferon gamma). Anti-IFNγ Antibody (B133.5) can be used for the research of immunology [1] .
    Anti-IFNγ Antibody (B133.5)
  • HY-149974
    CDK8-IN-13

    		Apoptosis CDK Cancer
    CDK8-IN-13 is a potent, selective and orally active CDK8 inhibitor with an IC50 value of 51.9 nM. CDK8-IN-13 induces apoptosis. CDK8-IN-13 decreases the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 shows antitumor activity [1].
    CDK8-IN-13
  • HY-RS16551
    Slc7a11 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Slc7a11 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc7a11 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Slc7a11 Mouse Pre-designed siRNA Set A
    Slc7a11 Mouse Pre-designed siRNA Set A
  • HY-179041
    SZ0232

    		PGE synthase Prostaglandin Receptor MDM-2/p53 Amino acid Transporter Glutathione Peroxidase Ferroptosis Metabolic Disease Endocrinology
    SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E2 (PGE2) and blocks the PGE2-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease [1] .
    SZ0232
  • HY-P990797
    Anti-Mouse IFN gamma Antibody (R4-6A2)

    		IFNAR Infection Inflammation/Immunology
    Anti-Mouse IFN gamma Antibody (R4-6A2) is an anti-mouse IFN gamma IgG1 monoclonal antibody. Anti-Mouse IFN gamma Antibody (R4-6A2) can increase the total serum IgG level. Anti-Mouse IFN gamma Antibody (R4-6A2) can be used for researches on immunology and infection conditions such as nymphs infection. The recommend isotype control of Anti-Mouse IFN gamma Antibody (R4-6A2): Rat IgG1 kappa, Isotype Control (HY-P99979) [1] .
    Anti-Mouse IFN gamma Antibody (R4-6A2)
  • HY-B0653
    Levobupivacaine
    2 Publications Verification

    (S)-(-)-Bupivacaine

    		 Sodium Channel Ferroptosis Neurological Disease Cancer
    Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer [1] .
    Levobupivacaine
  • HY-107429R
    Abrocitinib (Standard)

    PF-04965842 (Standard)

    		 Reference Standards JAK Inflammation/Immunology
    Abrocitinib (Standard) is the analytical standard of Abrocitinib. This product is intended for research and analytical applications. Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease [1].
    Abrocitinib (Standard)
  • HY-167692
    JI069

    		STAT Others
    JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.
    JI069
  • HY-RS22984
    Slc7a11 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Slc7a11 Rat Pre-designed siRNA Set A contains three designed siRNAs for Slc7a11 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Slc7a11 Rat Pre-designed siRNA Set A
    Slc7a11 Rat Pre-designed siRNA Set A
  • HY-N13614
    Centaurein

    		Bacterial IFNAR Nuclear Factor of activated T Cells (NFAT) NF-κB Infection Inflammation/Immunology
    Centaurein, a flavonoid, is an IFN-γ promoter enhancer. Centaurein up-regulates the activity of NFAT and NF-κB enhancers. Centaurein increases the IFN-γ expression in T and NK cells and the serum IFN-γ level in mice. Centaureidin completely relaxes the contractions in intact rat aortic rings. Centaurein effectively protects mice against Listeria infection [1][2][3][4].
    Centaurein
  • HY-160151
    TP1L

    		PROTACs Phosphatase JAK IFNAR MHC Cancer
    TP1L is a potent and selective T-cell protein tyrosine phosphatase (TC-PTP) PROTAC degrader, with a DC50 value of 35.8 nM. TP1L elevates the phosphorylation level of TC-PTP substrates including pSTAT1 and pJAK1. TP1L selectively enhances IFN-γ signaling and increases MHC-I expression. TP1L activates TCR signaling through increases phosphorylation of LCK. TP1L enhances CAR-T cell mediated tumor killing efficacy through activation of the CAR-T cells. TP1L can be used for the study of cancer. (Pink: TC-PTP ligand: (HY-138964), Blue: E3 ligase CRBN Ligand (HY-A0003), Black: Linker: (HY-140002)) [1].
    TP1L
  • HY-161016
    TNF/IFN-γ-IN-1

    		TNF Receptor IFNAR Neurological Disease
    TNF/IFN-γ-IN-1 (compound TGA) is a dual inhibitor of TNF and IFN-γ. TNF/IFN-γ-IN-1 can used in study Alzheimer’s disease [1].
    TNF/IFN-γ-IN-1
  • HY-115734
    Phenylpyropene C

    S14-95

    		 Acyltransferase Inflammation/Immunology
    Phenylpyropene C (S14-95), a JAK/STAT pathway inhibitor, can inhibit IFN-γ mediated expression of the reporter gene (IC50=5.4~10.8 μM). Phenylpyropene C also is an inhibitor of acyl-CoA, with an IC50 of 16.0 μM [1] .
    Phenylpyropene C
  • HY-B0069R
    Fludarabine (Standard)

    F-ara-A (Standard); NSC 118218 (Standard)

    		 Reference Standards Nucleoside Antimetabolite/Analog DNA/RNA Synthesis STAT Apoptosis Cancer
    Fludarabine (Standard) is the analytical standard of Fludarabine. This product is intended for research and analytical applications. Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes [1] .
    Fludarabine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: